Troglitazone

Troglitazone is an orally active thiazolidinedione having antidiabetic, hepatotoxic, and potentially antineoplastic effects. Troglitazone activates peroxisome proliferator-activated receptor gamma (PPARgamma), a ligand-activated transcription factor, causing cell differentiation while suppressing cell proliferation and angiogenesis. This drug also influences insulin-responsive gene transcription, suppresses macrophage and monocyte activation, and promotes adipocyte differentiation. Troglitazone is a thiazolidinone and a chromane. It is a hypoglycemic agent, antioxidant, vasodilator, anticonvulsant, anticoagulant, platelet aggregation inhibitor, antineoplastic agent, and ferroptosis inhibitor. Troglitazone functions similarly to the other thiazolidinediones (pioglitazone and rosiglitazone) by activating peroxisome proliferator-activated receptors (PPARs). Troglitazone includes a tocopherol moiety, which may confer vitamin E-like action in addition to PPAR activation. It has been...